Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 7/20 | 0.56 |
| ▸ | RORC | P51449 | 6/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | MTTP | P55157 | 2/20 | 0.39 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3619551 | 1.00 | NR1H3 (0.56) | NR1H3RORCNPSR1MEN1HTT | |
| SCHEMBL3619548 | 1.00 | NR1H3 (0.56) | NR1H3RORCNPSR1MEN1HTT | |
| SCHEMBL13317244 | 0.92 | MEN1 (0.47) | NR1H3RORCNPSR1MEN1HTT | |
| SCHEMBL13317250 | 0.92 | MEN1 (0.47) | NR1H3RORCNPSR1MEN1HTT | |
| SCHEMBL13317252 | 0.92 | MEN1 (0.47) | NR1H3RORCNPSR1MEN1HTT | |
| SCHEMBL3621615 | 0.91 | NPSR1 (0.46) | NR1H3RORCNPSR1MEN1HTT | |
| SCHEMBL3621612 | 0.91 | NPSR1 (0.46) | NR1H3RORCNPSR1MEN1HTT | |
| SCHEMBL3621618 | 0.91 | NPSR1 (0.46) | NR1H3RORCNPSR1MEN1HTT | |
| SCHEMBL15108517 | 0.90 | MEN1 (0.46) | NR1H3RORCNPSR1MEN1HTT | |
| SCHEMBL15108530 | 0.90 | MEN1 (0.46) | NR1H3RORCNPSR1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951676-B1 | N-ACYL BENZAZEPINE DERIVATIVES AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2392567-A1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1951676-A2 | LXR MODULATORS | Brystol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007050425-A2 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | NR1H3 2/4885RORC 66/4885NPSR1 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.